IDV vehicle
75A50118D00036
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $251.7M |
| Current contract value | Not reported |
| Potential contract value / ceiling | $636.6M |
| Start date | Sep 27, 2018 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Jul 29, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 27 of 27 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 29, 2026 | P00026 | $8.0M | BILATERAL NO-COST MODIFICATION EXTENDING POPS FOR CLINS 0003, 0007-0012; INCREASES CLIN 0012 BARDA FUNDING BY $8.009M AND GENENTECH COST SHARE BY $5.507M; TOTAL EXERCISED AGREEMENT VALUE INCREASED TO $251.709M. |
| Mar 26, 2026 | P00025 | $0 | THE PURPOSE OF THIS NO COST MOD IS TO REVISE ARTICLE IV, TO UPDATE GENENTECH'S VOTER FOR ALTEPLASE AND TO MODIFY THE STATEMENT OF WORK TO UPDATE ELIMINATE SUBCLIN PERIOD OF PERFORMANCE DATES. |
| Oct 1, 2025 | P00024 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO REVISE ARTICLE V, AGREEMENT ADMINISTRATION B, REPLACE THE GOVERNMENT POINTS OF CONTACT. |
| Jun 18, 2025 | P00023 | $0 | CORRECT POP DATES AND DELETE DELIVERY DATES |
| Jun 16, 2025 | P00022 | $5.6M | MOD SOW FOR CLINS 0007, 0010, AND 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT, CLIN 0012 TRAUMATIC BRAIN INJURY (TBI) DIAGNOSTICS AND MONITORING. ADD FUNDING AND MODIFY SOW. MODIFY ARTICLE VI (COST SHARING): THE TOTAL VALUE OF COMMITTED FUNDS FROM |
| May 5, 2025 | P00021 | $11.5M | THE PURPOSES OF THIS MODIFICATION ARE TO: 1. CLIN 0011 - LEPB NONCLINICAL AND CLINICAL DEVELOPMENT: ADD FUNDING OF $11,500,000.00 AND MODIFY THE STATEMENT OF WORK (SOW) TO SUPPORT CLINICAL AND NON-CLINICAL PHARMACOLOGY, RESISTANCE, AND SUSCEPTIBILI |
| Jan 10, 2025 | P00020 | $8.7M | 1) CLIN 0003, ALTEPLASE SULFUR MUSTARD INDICATION. EXTEND THE PERIOD OF PERFORMANCE. 2) CLIN 0011 LEPB NONCLINICAL AND CLINICAL DEVELOPMENT. ADD SUPPLEMENTAL WITHOUT MODIFYING THE STATEMENT OF WORK. 3) CLARIFY COMPOSITION OF THE JOC AND ITS VOTERS. |
| Oct 11, 2024 | P00019 | $0 | ADD LAURA SADDISON AS A NON-VOTING JOC MEMBER |
| Sep 26, 2024 | P00018 | $30.4M | EXERCISE CLIN 0012 FOR TBI DIAGNOSTIC AND MONITORING AND EXTEND CLIN 0009 COVASTIL PERIOD OF PERFORMANCE. |
| Jun 10, 2024 | P00017 | $-8.8M | DE-OBLIGATE CANCELING FUNDS FROM CLIN 0003. |
| Mar 13, 2024 | P00016 | $12.9M | SUPPLEMENTAL FUNDING, REVISE OTTR, AND REVISE STATEMENT OF WORK. |
| Nov 29, 2023 | P00015 | $0 | REVISE THE OTAO AND CORRECT PERIOD OF PERFORMANCES. |
| Jul 17, 2023 | P00014 | $0 | GENENTECH UMBRELLA AGREEMENT - UPDATE CLIN 0008 POP AND UPDATE SOW |
| Mar 23, 2023 | P00013 | $1.2M | GENENTECH UMBRELLA AGREEMENT |
| Jan 13, 2023 | P00012 | $0 | GENENTECH UMBRELLA AGREEMENT |
| Sep 24, 2022 | P00011 | $10.8M | GENENTECH UMBRELLA AGREEMENT |
| Jul 26, 2022 | P00010 | $0 | GENENTECH UMBRELLA AGREEMENT |
| Sep 22, 2021 | P00009 | $16.3M | GENENTECH UMBRELLA AGREEMENT |
| Mar 24, 2021 | P00008 | $3.0M | GENENTECH UMBRELLA AGREEMENT |
| Dec 21, 2020 | P00007 | $3.0M | GENENTECH UMBRELLA AGREEMENT |
| May 27, 2020 | P00006 | $22.6M | GENENTECH OTA - ACTIVATION OF CLIN 0009 FOR COVASTIL PHASE 2 RCT FOR COVID-19 |
| Mar 26, 2020 | P00005 | $25.1M | GENENTECH OTA - ACTIVATION OF CLIN 0008 FOR ACTEMRA PHASE 3 RCT FOR COVID-19 AND EXTENSION OF CLIN 0005 (LEPB) PERIOD OF PERFORMANCE TO DECEMBER 31, 2021 |
| Jan 27, 2020 | P00004 | $7.0M | GENENTECH OTA - ACTIVATION OF CLIN 0007 FOR LEPB / GDC-5780 PREPARATION FOR PHASE 1 ACTIVITIES |
| Sep 17, 2019 | P00003 | $25.0M | ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA |
| May 11, 2019 | P00002 | $6.0M | ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA |
| Dec 28, 2018 | P00001 | $0 | ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA |
| Sep 27, 2018 | 0 | $63.4M | ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.